Completed target enrollment in Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) in 2L+ Recurrent/Metastatic Head and ...

Pyxis Oncology has concluded its first multi-target sublicensing agreement under the new arrangement with a stealth ADC company. This expansion builds on the former agreement, which provided Pyxis ...

The average one-year price target for Pyxis Tankers (NasdaqCM:PXS) has been revised to $10.20 / share. This is an increase of 11.11% from the prior estimate of $9.18 dated February 21, 2026. The price ...

Pyxis Oncology needs to pave a longer cash runway. To do so, the Pfizer-partnered antibody-drug conjugate (ADC) biotech is cutting 40% of staff, slimming its programs and looking to monetize royalty ...

Pyxis Oncology PYXS announced that it has dosed the first patient in a phase I study of PYX-106, a fully human immunotherapy antibody candidate. The company's shares rose 4.15% on the pipeline ...

Pyxis Oncology is slimming down after a tough start to life on public markets, pausing work on two assets and stopping development of a third altogether to focus its cash on getting its lead programs ...

Stephens has initiated coverage on Pyxis Oncology Inc (NASDAQ:PYXS), highlighting the company’s technology platform aimed at developing next-gen antibody-drug conjugates (ADCs) with enhanced potency, ...

Blackmagic's latest test firmware build brings phase-detection autofocus to the PYXIS 6K, with linear focus support, ...